Skip to main content
OpenTrials
Withdrawn

NCT Number: NCT04612803

Antihistamines in the Treatment of Irritable Bowel Syndrome With Diarrhea

Irritable bowel syndrome is a functional disorder of the gastrointestinal tract diagnosed with the Rome criteria. The Rome IV criteria are based on abdominal pain symptoms and stool habits including stool frequency and stool forms [1]. They define 3 main subtypes based on symptoms: 1) IBS with diarrhea; 2) IBS with constipation: and 3) mixed symptoms of constipation and diarrhea. The IBS with diarrhea (IBS-D) subtype has the highest prevalence. Currently, treatment of IBS-D includes antidiarrheals, bile acid sequestrants, antispasmodics, tricyclic antidepressants, and FODMAP diet. However, many patients are intolerant or unresponsive to the above treatments. Outside of IBS, chronic diarrhea affects about 5% of adults. We have described a syndrome in a subset of IBS patients presenting with post prandial diarrhea, flushing and dermatographia whose symptoms are prevented by pre-treatment with combined H1 and H2 antihistamines [2]. However, the prevalence of this syndrome among the IBS + D patients is not known nor have the clinical characteristics or predictors of antihistamine responsive IBS + D been defined.

Why the study stopped: no funding for clinical research space
Withdrawn

Looking for future studies?

Notify Me

Key information

Age range

18 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 3

Primary location

UC Health

Cincinnati, Ohio, 45219, United States

About this study

We have published a series of 5 patients with chronic post prandial diarrhea (PPD) that begins within 3 hours after eating, associated with dermatographia, responsive to antihistamines [2]. In these cases, no underlying causes were identified to explain PPD; diagnoses of food allergy, lactose intolerance, celiac disease, dumping syndromes, inflammatory bowel disease, systemic mastocytosis were excluded. Patients with the syndrome have prior histories of chronic urticaria and experience associated transient symptoms of flushing, headache, tachycardia, and abdominal bloating during PPD episodes.

This syndrome, except for our published report, have not been previously described in the medical literature. Patients with systemic mastocytosis and mast cell activation syndrome experience PPD but along with anaphylactic manifestations (e.g. wheezing, hypotension) and measurable mast cell biomarkers are identifiable in affected patients (i.e. serum mast cell tryptase or 24 hour urine methylhistamine, PGF2a). Therefore, it is important to characterize PPD responsive to antihistamines in a general GI patient population and to publish our findings. The impact on human health will be substantial; we found that these patients are undiagnosed and untreated for many years.

Our aim is to recruit a minimum of 29 (with a maximum of 50) patients from community (third-party) and the UC Health affiliated primary care, allergy and/or gastroenterology clinics and the Bernstein Allergy Group David Bernstein MD, a faculty member in the Division of Immunology, Rheumatology, and Allergy, Yashu Dhamija MD (faculty), allergy fellows and GI fellows will direct and implement subject screening and consenting

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Age 18 years and older
  • Prior to Diagnosis of IBS + diarrhea based on ICD 10 codes with or without constipation unresponsive to prior treatments
  • Moderate to severe symptom severity score (>175 points) based on IBS symptom severity scale
  • Seeking evaluation by a health care professional
  • Negative serologic celiac panel
  • No response to lactose elimination diet by history
  • Normal colonoscopy
  • Able to complete symptoms diaries and global evaluations

Exclusion criteria

  • Confirmed IgE dependent food allergy as a cause of the gastrointestinal symptoms.
  • Lactose intolerance by history
  • Celiac disease by serology
  • Inflammatory bowel disease or colitis
  • Bile acid diarrhea by history
  • Post-surgical GI symptoms (e.g., dumping syndrome) by history
  • No colonoscopy performed
  • GI malabsorption
  • Current pregnancy
  • Current severe depression or history of psychosis
  • Current treatment with tricyclic antidepressants

Treatment and study plan

Antihistamine

Drug

Cetirizine 10 mg and famotidine 20 mg will be dispensed to each patient, to be taken twice a day at 6-9AM one hour before eating breakfast and again at evening 12 hours after the morning dose for 30 days

Other names: zyrtec, pepcid

Placebo

Drug

These medications will be pre-packaged by the UC Health pharmacy in a manner that results in a double-blinded cross-over design.

Primary outcomes

  1. IBS symptomy severity score

    Time frame: 135 days

    ≥50 point in reduction of symptoms with antihistamines based on the IBS symptom severity scale (IBS-SSS). This validated scale contains 5 questions that measures on a 100 point scale (for a total of 500 points) the severity of abdominal pain, frequency of abdominal pain, severity of abdominal distension, dissatisfaction with bowel habits, and interference with quality of life.

Secondary outcomes

  1. IBS quality of life

    Time frame: 135 days

    ≥10 point improvement in Quality of Life (IBS-QOL) questionnaire and a "moderately improved" or "substantially improved" on the IBS global assessment of improvement (IBS-GAI) scale. The IBS-QOL is a 34-item questionnaire which assesses the degree to which IBS interferes with the patient's quality of life. The IBS-GAI asks one question that assesses the overall improvement in symptoms in the past 7 days.

Sponsors and collaborators

Lead sponsor

University of Cincinnati

Other

Registry information

Official study title

Antihistamines in the Treatment of Irritable Bowel Syndrome With Diarrhea: a Cross-Over Trial

Important dates

Study start
2020
Primary completion
2026
Study completion
2026
First posted
Nov 3, 2020
Registry last updated
Sep 4, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.